Boussinesq M
Institut de Recherche pour le Développement (IRD), UR024, Département Sociétés et Santé, 213 rue La Fayette, 75480 Paris Cedex 10, France.
Ann Trop Med Parasitol. 2006 Dec;100(8):715-31. doi: 10.1179/136485906X112194.
Loiasis affects millions of individuals living in the forest and savannah regions of Central Africa. In some areas, this disease constitutes one of the most common reasons for medical consultation. The burden posed by loiasis is probably under-estimated and, in addition, individuals harbouring high Loa microfilarial loads are at risk of developing serious neurological reactions after treatment with diethylcarbamazine or ivermectin. These events are currently significantly hampering the development of the African Programme for Onchocerciasis Control, and operational research is required to address the issue. The results of recent studies, involving either human populations from endemic areas or monkey models, have provided much more detail of the mechanisms associated with amicrofilaraemic or so-called 'occult' loiasis. New diagnostic tools have also been developed in the last decade, and various protocols are now available for the risk-free treatment of loiasis cases.
罗阿丝虫病影响着数百万生活在中非森林和草原地区的人。在一些地区，这种疾病是就医的最常见原因之一。罗阿丝虫病造成的负担可能被低估了，此外，携带高负荷罗阿微丝蚴的个体在接受乙胺嗪或伊维菌素治疗后有发生严重神经反应的风险。这些事件目前严重阻碍了非洲盘尾丝虫病控制规划的进展，因此需要开展运筹学研究来解决这一问题。最近涉及流行地区人群或猴子模型的研究结果，提供了与无微丝蚴血症或所谓“隐匿性”罗阿丝虫病相关机制的更多细节。在过去十年中还开发了新的诊断工具，现在有各种方案可用于罗阿丝虫病病例的无风险治疗。
